Research map: Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting

Back to the article

Papers in this map

  1. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN · Hartmut Döhner · 2022 · 3298 citations · Cited by this paper
  2. Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation · 2026 · Related
  3. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations · Hartmut Döhner · 2024 · 242 citations · Cited by this paper
  4. Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications · 2026 · Related
  5. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML · Wei‐Ying Jen · 2025 · 14 citations · Cited by this paper
  6. Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML · 2026 · Related
  7. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: Phase 1b results from KOMET-007 · Gail J. Roboz · 2025 · 13 citations · Cited by this paper
  8. Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma · 2026 · Related
  9. Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study · Jessica Kaplan Altman · 2025 · 12 citations · Cited by this paper
  10. Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting · 2026 · Related
  11. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia · Roberta Santos Azevedo · 2025 · 6 citations · Cited by this paper
  12. Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma · 2026 · Related
  13. γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction · Sylvain Garciaz · 2025 · 4 citations · Cited by this paper
  14. Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types · 2026 · Related
  15. A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia · Sankalp Arora · 2025 · 3 citations · Cited by this paper
  16. Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy · 2026 · Related
  17. Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome · Roberta Santos Azevedo · 2025 · 2 citations · Cited by this paper
  18. Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer · 2026 · Related
  19. Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit Acute Myeloid Leukemia (AML): A multicenter, open-label prospective study · Ligen Liu · 2025 · 1 citation · Cited by this paper
  20. Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy · 2026 · Related
  21. Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML · Curtis Andrew Lachowiez · 2025 · 1 citation · Cited by this paper
  22. Results of the Phase 1B study of pegargiminase (ADI-PEG 20) in combination with AZA-VEN in newly diagnosed high-risk AML patients not candidates for intensive chemotherapy · Justin M. Watts · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)